OR WAIT null SECS
It is important to understand the differences between risk-based decision making and other decision making in a pharmaceutical quality system.
Validating computerized systems is required to demonstrate adherence to data integrity, says Susan J. Schniepp, distinguished fellow at Nelson Laboratories, LLC.
Quality-by-design risk assessment workflows can be laborious and have limited capacity to connect with vast volumes of prior knowledge generated by organizations. ecosystem.
April 18, 2023
Gamida Cell’s therapy is meant to reduce the risk of infection following stem cell transplantation.
April 14, 2023
FDA has granted fast track designation to Caribou Biosciences for its allogeneic CAR-T cell therapy for relapsed or refractory multiple myeloma.
April 11, 2023
A document signed by members of more than 400 companies and investment firms decries the decision made by a federal judge concerning mifepristone, a medication used in abortions.
April 10, 2023
Will court challenges to FDA’s oversight authority open the door for multiple lawsuits to block agency decisions on all sides?
April 07, 2023
The agency is dealing with high demand for staff because of a surge in the development of cell and gene therapies.
FDA aims to address mounting criticisms of its accelerated approval pathway.
April 05, 2023
Change management is central to the evolution of quality control laboratories, but what factors can maximize patient outcomes?
April 03, 2023
Impurities and batch-to-batch variability present the biggest challenges.
April 02, 2023
New child-friendly treatment options and initiatives are improving the outlook of children living with HIV in Europe.
FDA has spurred investment to create and develop 600 therapies.